Item 8.01. Other Events
On August 26, 2020, CVS Health Corporation, a Delaware corporation (the
"Company"), issued press releases announcing the (A) early results and
(B) pricing, respectively, of its cash tender offers (each, a "Tender Offer" and
collectively, the "Tender Offers") for (i) up to $3,000,000,000 aggregate
principal amount (the "2023 Notes Maximum Amount") of its 4.000% Senior Notes
due 2023 and 3.700% Senior Notes due 2023 and the 2.800% Senior Notes due 2023
issued by its wholly-owned subsidiary, Aetna Inc. (collectively, the "2023
Notes") and (ii) up to $3,000,000,000 aggregate principal amount (the "2025
Notes Maximum Amount" ) of its 4.100% Senior Notes due 2025 and 3.875% Senior
Notes due 2025 (collectively, the "2025 Notes", and, together with the 2023
Notes, the "Notes") validly tendered and accepted for purchase in connection
with the Company's previously announced cash tender offers commenced on
August 12, 2020. The sum of the 2023 Notes Maximum Amount and the 2025 Notes
Maximum Amount is $6,000,000,000 (the "Aggregate Maximum Amount").
Because the Company expects to accept for purchase the Maximum Aggregate Amount
of Notes, no additional Notes will be purchased pursuant to the Tender Offers
after August 27, 2020, the early settlement date for such Notes validly tendered
and accepted for purchase by the Company.
Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2,
which are incorporated by reference herein.
© Edgar Online, source Glimpses